Literature DB >> 18083693

The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO).

P G Casali.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 18083693     DOI： 10.1093/annonc/mdm517

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  20 in total

Review 1.  Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.

Authors:  Rosa Lerose; Pellegrino Musto; Michele Aieta; Carla Papa; Alfredo Tartarone
Journal:  Eur J Clin Pharmacol       Date:  2011-12-14       Impact factor: 2.953

2.  Conflict of interest disclosure in off-label oncology clinical trials.

Authors:  Blair Irwin; Bradford R Hirsch; Gregory P Samsa; Amy P Abernethy
Journal:  J Oncol Pract       Date:  2012-06-26       Impact factor: 3.840

3.  Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study.

Authors:  M Joerger; C Schaer-Thuer; D Koeberle; K Matter-Walstra; J Gibbons-Marsico; S Diem; B Thuerlimann; T Cerny
Journal:  Eur J Clin Pharmacol       Date:  2014-03-11       Impact factor: 2.953

4.  Availability and quality of illegitimate somatropin products obtained from the Internet.

Authors:  Róbert György Vida; András Fittler; Ivett Mikulka; Eszter Ábrahám; Viktor Sándor; Ferenc Kilár; Lajos Botz
Journal:  Int J Clin Pharm       Date:  2016-11-25

Review 5.  DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment.

Authors:  Denise Bernhardt; Laila König; Anca-L Grosu; Stefan Rieken; Sandro M Krieg; Wolfgang Wick; Benedikt Wiestler; Friederike Schmidt-Graf; Felix Sahm; Jens Gempt; Bernhard Meyer; Bernd J Krause; Cordula Petersen; Rainer Fietkau; Michael Thomas; Frank Giordano; Andrea Wittig-Sauerwein; Jürgen Debus; Ghazaleh Tabatabai; Peter Hau; Joachim Steinbach; Stephanie E Combs
Journal:  Strahlenther Onkol       Date:  2022-08-29       Impact factor: 4.033

6.  Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).

Authors:  R Colomer; E Alba; A González-Martin; L Paz-Ares; M Martín; A Llombart; Á Rodríguez Lescure; J Salvador; J Albanell; D Isla; M Lomas; C A Rodríguez; J M Trigo; J R Germà; J Bellmunt; J Tabernero; R Rosell; E Aranda; R Cubedo; J Baselga
Journal:  Ann Oncol       Date:  2010-02       Impact factor: 32.976

7.  Identification of risks associated with the prescribing and dispensing of oral anticancer medicines in Ireland.

Authors:  Lisa Hammond; Elaine Marsden; Niamh O'Hanlon; Fionnuala King; Martin Charles Henman; Claire Keane
Journal:  Int J Clin Pharm       Date:  2012-09-09

8.  Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China.

Authors:  Weilan Wang; Man Zhu; Daihong Guo; Chao Chen; Dongxiao Wang; Fei Pei; Liang Ma
Journal:  Iran J Public Health       Date:  2013-05-01       Impact factor: 1.429

Review 9.  Regulating off-label drug use in India: The arena for concern.

Authors:  Sukhvinder Singh Oberoi
Journal:  Perspect Clin Res       Date:  2015 Jul-Sep

10.  Severe thrombocytopenia in a patient with hepatitis C treated with eltrombopag from off-label drug use to on-label drug use: a case report.

Authors:  Hassan A Al-Jafar; Jameela Al-Khaldi; Ahmad Alduaij; Khalifa Al-Banwan
Journal:  J Med Case Rep       Date:  2014-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.